FibroBiologics(股票代码:FBLG)近日宣布,其针对退行性椎间盘疾病研发的成纤维细胞球源性软骨细胞(Fsdc)球疗法在临床前研究中取得积极成果。该疗法展现出了良好的治疗潜力,为后续的临床开发奠定了坚实基础。
FibroBiologics(股票代码:FBLG)近日宣布,其针对退行性椎间盘疾病研发的成纤维细胞球源性软骨细胞(Fsdc)球疗法在临床前研究中取得积极成果。该疗法展现出了良好的治疗潜力,为后续的临床开发奠定了坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.